Histological and genetic markers for non-small-cell lung cancer: Customizing treatment based on individual tumor biology
- 1 January 2010
- journal article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 67 (1_Suppleme), S3-S9
- https://doi.org/10.2146/ajhp090456
Abstract
Purpose. To describe how molecular and genetic markers influence the response to therapy in patients with advanced non-small-cell lung cancer (NSCLC).Keywords
This publication has 21 references indexed in Scilit:
- Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and ChemotherapyJournal of Clinical Oncology, 2008
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant ChemotherapyNew England Journal of Medicine, 2006
- Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene MutationsJournal of Clinical Oncology, 2006
- Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxelMolecular Cancer Therapeutics, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancerHuman Molecular Genetics, 2004
- Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional SurgeryClinical Cancer Research, 2004
- The Hallmarks of CancerCell, 2000
- EGF receptorThe International Journal of Biochemistry & Cell Biology, 1999
- The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiationBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1996